You searched for "retinal"
Fingolimod: ocular adverse effects
In this article the authors review the ocular side-effects of Fingolimod which is an oral immunomodulating drug used in the management of relapsing-remitting multiple sclerosis (RRMS). Fingolimod-associated macular oedema (FAME) is the most common ocular side-effect linked to this drug....
Clinical presentation, management, and outcomes in posterior segment open globe injuries
This is a retrospective, non-comparative, interventional case study of patients presenting with scleral and corneoscleral wounds covering a five-year period. It reports the clinical presentation, management, and factors affecting the outcomes of posterior segment open globe injuries (OGI) in 2360...Pioneering eye device restores reading vision to blind eyes
A pivotal European clinical trial of a new electronic eye implant has seen remarkable results. The study, published in the New England Journal of Medicine, showed 84% of participants were able to read letters, numbers and words using prosthetic vision...Sense Medical and Canon: Getting ready for the OCT Pathway in Diabetic Eye Screening Surveillance Pathway webinar
Are you ready for the OCT pathway in DESP? OCT is set to be integrated into the English National Diabetic Eye Screening Surveillance Pathway, significantly enhancing the management of patients with mild diabetic maculopathy. This advancement allows patients to remain within a surveillance pathway overseen by retinal screening rather than being immediately referred to the Hospital Eye Service (HES). The webinar will be hosted by Professor Tunde Peto and Mrs Samantha Mann and will discuss the new OCT pathway, how OCT will change diabetic screening, how to interpret OCT images and how programmes can get ready for the change. Starts at 6pm UK time for 90 minutes
Macular atrophy with aflibercept
The authors of this paper set out to investigate the prevalence of macular atrophy in treatment-naive patients with neovascular AMD undergoing aflibercept monotherapy (three monthly loading injections followed by subsequent treatment every two months). Case notes over a three year...
Results of fixed aflibercept treatment regime in type 3 neovascularisation
In this prospective study the authors evaluate the effect of intravitreal aflibercept injections in the treatment of naive type 3 neovascularisation using a fixed treatment regime. Fourteen eyes of 14 patients were studied. All patients were treated with intravitreal 2.0...
The evolution and visual prognosis of glial proliferation of different grades after macular hole surgery
This retrospective research study aimed to investigate the evolution of glial proliferation of varying grades after successful idiopathic macular hole repair and its effects on foveal microstructure and best-corrected visual acuity (BCVA). Two-hundred and two eyes were enrolled in this...Updated Guidance for Professional Practice published by College of Optometrists
The College of Optometrists has today (11 December) published updated Guidance for Professional Practice for optometrists, including new sections.The Sickle Cell Retinopathy Network is leading global change in screening and management
Sickle cell disease or disorder (SCD) is one of the most neglected health conditions in the world. A strong hypothesis is that this is because SCD affects people of African, Caribbean and other Global Majority communities and has received disproportionately...
Aflibercept for the treatment of neovascular glaucoma
The aim of this study was to investigate initial results regarding the treatment of neovascular glaucoma (NVG) with intravitreal aflibercept. NVG is classified into stages 0-3. In stages 1 and 2, abnormal vessel proliferation is seen with or without elevated...
Anatomical and functional outcomes following switching from aflibercept to ranibizumab in NARMD
This is a six-month, prospective, single-arm study in the UK and Germany. A total of 100 patients were enrolled (one in the primary failure group, 99 in the suboptimal treatment response group), treated three-monthly intravitreal ranibizumab injections (0.5mg), and then...
